Former Chief Financial Officer, Secretary, and Treasurer · Monopar Therapeutics (MNPR)

Karthik Radhakrishnan

FY2024 is the first fiscal year CompBrief holds for Karthik Radhakrishnan as a named executive officer of Monopar Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$320,160

Salary $192,400Stock awards $0

3rd of 3 named executive officers at Monopar Therapeutics by FY2024 total.

3 named officers on file for Monopar Therapeutics, FY2024

Karthik Radhakrishnan’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Monopar Therapeutics’s whole pay program stands against its peers

  • Monopar Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MNPR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2025 (DEF 14A).

Free

Get Karthik Radhakrishnan’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Karthik Radhakrishnan compensation by year

Monopar Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Monopar Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$192,400
Bonus$0
Stock awards$0
Option awards$73,888
Non-equity incentive$0
Pension and deferred compensation$0
All other$53,872
Total$320,160

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Monopar Therapeutics DEF 14A filed April 30, 2025, accession 0001437749-25-013824, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Monopar Therapeutics filed document, accession 0001437749-25-013824. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option21,875—$3.71

Per the Outstanding Equity Awards at Fiscal Year-End table in Monopar Therapeutics's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Monopar Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Chandler RobinsonChief Executive Officer and Director$1,144,480
Andrew CittadineChief Operating Officer$554,796
Karthik Radhakrishnan · this pageFormer Chief Financial Officer, Secretary, and Treasurer$320,160

The full Monopar Therapeutics compensation record

free company brief

This page is one person within Monopar Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Monopar Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Karthik Radhakrishnan's compensation dossier · One-time report. No refunds.